BioMarin Pharmaceutical

Latest news

• What BioMarin Pharmaceutical (BMRN)'s AI Drug Discovery Deal Means For Shareholders (opens in a new tab)

  Simply Wall Street · Oct 2, 2026

• After 4,086 shares were delivered or withheld, BioMarin (BMRN) R&D chief holds 47,732 shares. (opens in a new tab)

  Stock Titan · Oct 1, 2026

• The Strategic Financial Case for BioMarin Pharmaceutical (BMRN) (opens in a new tab)

  Yahoo Finance · Oct 1, 2026

• BioMarin and Profluent partner on AI-designed enzyme therapies (opens in a new tab)

  Pharmaceutical Technology · Oct 1, 2026

• BioMarin Pharmaceutical (BMRN) Could Be 35% Undervalued Following Profluent AI Collaboration (opens in a new tab)

  Simply Wall Street · Oct 1, 2026

• BioMarin Pharmaceutical stock weighs VOXZOGO setback against growth (opens in a new tab)

  AD HOC NEWS · Sep 30, 2026

• Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026 (opens in a new tab)

  TradingView · Sep 30, 2026

• BioMarin Grants Ascendis Global License, Secures Royalty Revenues (opens in a new tab)

  tipranks.com · Sep 30, 2026

• BioMarin Licenses CNP IP to Ascendis; 20% US, 18% EU/Brazil/S. Korea Royalties Until May 2030 (opens in a new tab)

  TradingView · Sep 30, 2026

• BioMarin lays off 117 California workers to consolidate footprint (opens in a new tab)

  Fierce Pharma · Sep 30, 2026

• Profluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI (opens in a new tab)

  marketscreener.com · Sep 30, 2026

• Profluent Partners With BioMarin to Design Novel Medicines Using AI (opens in a new tab)

  Business Wire · Sep 30, 2026

• Layoff Tracker: Novo, BioMarin, Enanta dole out pink slips (opens in a new tab)

  BioSpace · Sep 30, 2026

• BioMarin Pharmaceutical (BMRN) Adds Robert Plenge To Its Board (opens in a new tab)

  Simply Wall Street · Sep 26, 2026

• BioMarin Pharmaceutical stock holds at $63.94 as analysts stay bullish (opens in a new tab)

  AD HOC NEWS · Sep 23, 2026

• BioMarin Pharmaceutical stock holds near its 52-week low (opens in a new tab)

  AD HOC NEWS · Sep 22, 2026

• BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN) (opens in a new tab)

  Seeking Alpha · Sep 21, 2026

• BioMarin Pharmaceutical stock holds near a $12.38 billion value (opens in a new tab)

  AD HOC NEWS · Sep 20, 2026

• What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)? (opens in a new tab)

  Yahoo Finance · Sep 19, 2026

• BioMarin stock steadies after September 17 close (opens in a new tab)

  AD HOC NEWS · Sep 18, 2026

• BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone (opens in a new tab)

  Yahoo Finance · Sep 18, 2026

• What BioMarin Pharmaceutical Shares' Phase 3 Growth Data Means For Shareholders (opens in a new tab)

  Simply Wall Street · Sep 17, 2026

• BioMarin Pharmaceutical Grants Director Robert M Plenge 6,140 Shares at No Cost (NASDAQ: BMRN) (opens in a new tab)

  Kalkine Media · Sep 15, 2026

• BioMarin's stock target raised to $97 after pos... (opens in a new tab)

  Pluang · Sep 15, 2026

• BioMarin drops Voxzogo development for Noonan syndrome as treatment landscape shifts (opens in a new tab)

  Fierce Pharma · Sep 15, 2026

• Form 8K Biomarin Pharmaceutical Inc For: 14 September By Investing.com (opens in a new tab)

  Investing.com India · Sep 14, 2026

• BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors (opens in a new tab)

  PR Newswire · Sep 14, 2026

• BioMarin (NASDAQ: BMRN) director awarded 6,140 stock units (opens in a new tab)

  Stock Titan · Sep 14, 2026

• BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Appoints BMS R&D Chief Robert Plenge to Board (opens in a new tab)

  TradingView · Sep 14, 2026

• BioMarin Appoints Bristol Myers Squibb Research Chief Robert Plenge to Board (opens in a new tab)

  citybiz.co · Sep 14, 2026